Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Changli Wang et al.|The Lancet Oncology|2011Cited by 4.1k
miRNA-140-5p Play an Important Role of Parkinson's Disease DevelopmentMing Ye, Xiaolin Liu, Yuhua Chen et al.|Journal of Biomaterials and Tissue Engineering|2018Cited by 4